HTDS.US Hard to Treat Diseases Inc

Healthcare Biotechnology USA Stocks
0.0000 USD
Close of Oct 14, 2026
Market cap
USD 110K
P/E
-
P/B
-
ROE
21.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2010.

Is HTDS.US undervalued?

Graham number

The Graham number of Hard to Treat Diseases Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Hard to Treat Diseases Inc fundamental analysis

No fundamental analysis for Hard to Treat Diseases Inc yet.

Hard to Treat Diseases Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Hard to Treat Diseases Inc

Hard to Treat Diseases Inc. manufactures, supplies, and exports human vaccines and biological products in China and internationally. The company offers human vaccines, such as recombinant human papillomavirus bivalent, freeze-dried live attenuated hepatitis A, recombinant hepatitis E, meningococcal polysaccharide, 23-valent pneumococcal polysaccharide, varicella, rabies, group ACYW135meningococcal conjugate, inactivated poliomyelitis, enterovirus Type 71, influenza, meningoc…

Full company profile